Why Your BMI Might Not Tell the Real Story About Your Health

A major shift in how doctors diagnose obesity could change who gets prescribed weight-loss medications and who doesn't. Instead of relying solely on body mass index (BMI)—a simple calculation based on height and weight—new clinical guidelines propose identifying "clinical obesity" based on whether someone actually has organ damage or functional limitations from excess weight. This distinction matters because many people with high BMIs are metabolically healthy, while some with lower BMIs may have serious health complications.

What's Wrong With Using BMI Alone?

For decades, doctors have diagnosed obesity by checking a single number: BMI. If your BMI exceeded a certain threshold (typically 30 or higher, roughly 215 pounds for someone 5'10"), you were labeled as having obesity and often told to lose weight or consider medications like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). But BMI has a fundamental flaw—it measures total body weight, not body fat distribution or overall health status.

"The biggest change is separating clinical obesity, which they define as a disease from obesity as a body type with too much fat," explains Dr. Yen-Yi Juo, MD, MPH, who studied how these new guidelines apply to real-world populations. "So right now, most doctors, including bariatric surgeons or obesity doctors, most of us, we diagnose obesity by body mass index alone. So if someone has a high body mass index, you're labeled as having obesity, and then you're told to lose weight." The problem: not everyone with a high BMI is actually sick.

How Would the New Framework Change Diagnosis?

The Lancet Commission's proposed clinical obesity framework introduces a more nuanced approach. Under these guidelines, doctors would diagnose clinical obesity only when a person has both a high BMI AND evidence of organ dysfunction or daily living limitations. This might include complications like fatty liver disease, type 2 diabetes, joint problems, or difficulty performing everyday activities.

The practical impact is significant. Someone with a high BMI but no health problems wouldn't automatically qualify for weight-loss medications or bariatric surgery. Instead, doctors would conduct a thorough workup, ensure the person is metabolically healthy, and discuss their future disease risk without prescribing treatment. This represents a fundamental reframing: obesity as a disease state, not simply a body type.

Dr. Juo's research applying these guidelines to national population data revealed a substantial gap. Many people who currently qualify for FDA-approved weight-loss medications under existing BMI thresholds would not meet the clinical obesity criteria. "There's a very big gap between the people that actually have clinical obesity and people that will fit treatment indication, and these people in between the two thresholds, they actually don't have obesity as a disease," Dr. Juo notes. "But then according to FDA indications, doctors can prescribe all of them drugs, and I think that's something we need to pay attention to".

What Role Do Waist Measurements Play?

The new framework also incorporates alternative body measurements beyond BMI, including waist circumference and waist-to-hip ratio. These measurements better reflect how fat is distributed around the body—a key factor in disease risk, since fat stored around the abdomen poses greater health risks than fat stored elsewhere.

However, Dr. Juo's analysis found that adding these measurements made less practical difference than expected. Once BMI exceeds 35 (roughly 245 pounds for someone 5'10"), it becomes uncommon for someone to have a high BMI but normal waist circumference. Still, the framework's emphasis on multiple measurements reinforces an important principle: BMI alone isn't sufficient for understanding someone's health status.

Who Could Be Left Behind by These Changes?

While the clinical obesity framework offers benefits for individual patient care, it raises equity concerns. The new approach assumes people have regular medical checkups and screening tests—a luxury not equally available to everyone. Consider these potential disparities:

• Screening Access: Many obesity-related complications are "silent," meaning people don't know they have them. For example, fatty liver disease often goes undetected unless someone receives routine liver ultrasounds, which happen more frequently during enhanced medical surveys than during standard office visits.
• Socioeconomic Barriers: Obesity occurs more frequently in socioeconomically disadvantaged communities where access to routine preventive care is lower, meaning some patients may be diagnosed later simply because they weren't regularly screened.
• Documentation Requirements: If diagnosis depends on documented organ dysfunction, patients without consistent healthcare access may not have the medical records needed to prove they meet clinical obesity criteria, potentially delaying treatment.

Dr. Juo emphasizes that the clinical obesity framework is designed as a clinical tool for individual providers, not as a public health policy mandate. "The clinical obesity framework is very useful for individual clinicians. It helps guide clinicians to plan their treatment, their workup, but it's not designed as a public health policy tool. They're not advocating that we're going to reduce obesity funding or access to care just because fewer people meet clinical obesity criteria".

What Would Implementation Actually Require?

Adopting these guidelines widely would require significant changes to how clinics operate. The list of potential organ dysfunctions and functional limitations is extensive—so extensive that most providers don't systematically review all of them during routine visits. To make the framework practical, healthcare systems would need to build structured tools into electronic health records.

Dr. Juo suggests that an "obesity review of systems" built into electronic health records could help. Providers could check boxes for relevant organ systems and functional impairments, making it easier to determine whether a patient meets clinical obesity criteria and to document findings clearly. Without such structural support, the framework risks becoming too cumbersome for busy clinicians to implement consistently.

The bottom line: the shift from BMI-only diagnosis to clinical obesity assessment represents a more thoughtful approach to weight management. It acknowledges that not everyone with excess weight needs medication or surgery, while ensuring that people with genuine obesity-related disease get appropriate treatment. But success depends on equitable access to screening and clear clinical tools—challenges that healthcare systems will need to address as these guidelines potentially reshape obesity care.